Fig. 1: In vitro effects of idelalisib and duvelisib on T cell proliferation and differentiation. | Blood Cancer Journal

Fig. 1: In vitro effects of idelalisib and duvelisib on T cell proliferation and differentiation.

From: Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors

Fig. 1

A Impact of the indicated concentrations of idelalisib (Idela) and duvelisib (Duv) on CD3 T cell proliferation as measured by Cell Trace Violet dye. Proliferation index was quantified using Modfit. B In vitro effects of idelalisib and duvelisib at 10 μM on differentiation of naive CD4+ T cells to Th1 (T-bet), Th2 (GATA-3), Th17 (RORγT), and Treg (FOXP3) phenotypes. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

Back to article page